Bharat Biotech to set up ‘Biotech Pharma IT Park’ in Orissa for Rs 100 crore

A biotechnology incubation centre will also be developed within the park

Bharat Biotech has won the first public private partnership from the government of Orissa to start a biotech pharma park in the state’s proposed venture to promote pharma, biotech and IT sectors.

Bharat Biotech has been allocated 54.86 acres of land by the state government of Orissa towards the development of an integrated industrial park to attract and promote pharmaceutical, biotechnology and information technology industries in Bhubaneswar in the private public partnership mode.

The land has been allocated in the form of a long term lease to Bharat Biotech with commitments of time bound development of infrastructure and facilities.

The Orissa State Government is developing a state of the art Biotech Pharma IT Park over an area about 64.86 acres at Mouza-Andharua, Bhubaneswar on public-private-partnership (PPP).

The proposed park, the first of its kind in Orissa envisages promotion of biotech, pharmaceuticals and IT industries in the state.

Bharat Biotech will form a Special Purpose Vehicle (SPV) to develop the BT-Pharma-IT Park at Andharua.

The SPV will execute the Lease cum Development Agreement of the Bharat Biotech with Orissa Industrial Infrastructure Development Corporation (IDCO).

The estimated cost for development of the project by  Bharat Biotech International Limited, Hyderabad is about Rs.100 crores.

Bharath Biotech plans to complete the project in 8 years.

The state Govt of Orissa and IDCO have agreed to provide all external infrastructure facilities, such as road connectivity, water supply, power supply with 33KVA sub-station etc to facilitate rapid development of internal infrastructure.

Bharat Biotech will develop a Biotechnology Incubation Centre within this Park over another 10 acres for use by researchers, entrepreneurs and students.

The Department of Biotechnology, Govt of India, has assured funding for the equipment/instrumentation of this center of excellence within the park and Bharat Biotech will provide the necessary building infrastructure.

Bharat Biotech’s development of this integrated park would help kick start investments in the areas of biotechnology and pharmaceuticals in Orissa.

Orissa has recently selected  Bharat Biotech International Ltd as the ‘Developer’ for this ambitious project.

Bharat Biotech has experience in the development and commercialization of technology parks in India.

For example, Bharat Biotech has developed an integrated food biotech park in Bangalore.

Bharat Biotech was also instrumental in the establishment and development of the Genome Valley BioPharmaceutical cluster located in the outskirts of Hyderabad.

Bharat Biotech proposes to focus on rapid development of this park by developing core infrastructure and technology to enable establishment of new companies whereby new local entrepreneurs in biotechnology field will be created, the company said in a press release.

Bharat Biotech will also strive to bring in biotechnology, pharmaceuticals and IT industries in Orissa.

Bharat Biotech will also help in the creation and up gradation of skills in human resources in the areas of biotechnology, pharmaceutical sciences and information technology in Orissa.

Based in  Hyderabad, southern India,Bharat Biotech International Limited, is a biotechnology company specializing in product-oriented research, development and manufacturing of vaccines and biotherapeutics.

Bharat Biotech is the first bio-pharma facilities in India to be audited and approved by Korean Food & Drugs Administration (KFDA).

Bharat Biotech is situated at Genome Valley, Hyderabad, built with an investment of over USD 100 million. The facility’s manufacturing, control procedures and protocols, conform to the stringent standards laid down by internationally recognized institutions such as USFDA, UKMCA and WHO.

Bharat Biotech claims to the the first to manufacture,Idikinase, a recombinant streptokinase and Biogit, a yeast based probiotic yeast product in India.

Bharat Biotech has commercialized India’s first recombinant epidermal growth factor, Regen-D to treat diabetic foot ulcers, burns.

Bharat Biotech has a pipeline of vaccines to combat malaria, rotavirus and Japanese encephalitis infections.